Stability Indicating Liquid Chromatographic Method for the Simultaneous Determination of Rosuvastatin and Ezetimibe from Pharmaceuticals and Biological Samples
Open Access
- 30 October 2020
- journal article
- research article
- Published by The Turkish Chemical Society in Journal of the Turkish Chemical Society Section A: Chemistry
- Vol. 7 (3) , 865-874
Abstract
Fixed dose combinations of ezetimibe and rosuvastatin are well known to provide significantly superior efficacy to rosuvastatin alone in lowering total cholesterol, and triglyceride levels. Therefore, in this recent work, we prepared fixed dose (10mg/10mg) ezetimibe and rosuvastatin tablet formulations, and a simple, selective and we established and validated rapid chromatographic method for the sensitive and simultaneous determination of rosuvastatin and ezetimibe. We performed the separation on Zorbax SB-C18 (100 mm x 4.6 mm, 3.5 µm particle size) column at 30 oC with a mobile phase that has a composition as water containing 0.1% H3PO4:methanol:acetonitrile (50:25:25 v/v/v) at 1.2 mL/min flow rate. We further performed validation studies according to ICH guidelines. Furthermore, we exposed rosuvastatin and ezetimibe to degradation conditions. We plotted peak area vs. concentration graphs for rosuvastatin and ezetimibe and used for defining the linearity of the detector response. In this suggested method, we observed linear relationships varying from 0.05 to 50 µg/mL for ezetimibe concentrations and from 0.05 to 25 µg/mL for rosuvastatin concentrations. We found the limit of detection values for rosuvastatin and ezetimibe as 0.006 and 0.008 µg/mL, respectively. Moreover, we further used the established method for to the analysis of ezetimibe and rosuvastatin from real spiked samples of rabbit serum.Keywords
Funding Information
- Ankara Universitesi (BAP 17B0237002)
This publication has 27 references indexed in Scilit:
- Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: Method development, validation and optimization of various experimental parametersJournal of Chromatography B, 2011
- Development and Validation of Stability-Indicating HPLC Methods for Quantitative Determination of Pravastatin, Fluvastatin, Atorvastatin, and Rosuvastatin in PharmaceuticalsAnalytical Letters, 2009
- Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study)The American Journal of Cardiology, 2007
- Pharmacodynamic interaction between ezetimibe and rosuvastatinCurrent Medical Research and Opinion, 2004
- Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemiaExpert Opinion on Investigational Drugs, 2002
- Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.The American Journal of Cardiology, 2001
- Coronary heart disease: seven dietary factorsThe Lancet, 1991
- Can lifestyle changes reverse coronary heart disease?The Lancet, 1990
- HypercholesterolemiaThe Nurse Practitioner, 1990
- The Pathogenesis of Atherosclerosis — An UpdateNew England Journal of Medicine, 1986